Amarin Corporation plc (AMRN)
NASDAQ: AMRN · IEX Real-Time Price · USD
0.785
-0.005 (-0.65%)
At close: Jul 19, 2024, 4:00 PM
0.790
+0.005 (0.66%)
Pre-market: Jul 22, 2024, 7:41 AM EDT
Amarin Corporation Revenue
Amarin Corporation had revenue of $277.46M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $56.52M. In the year 2023, Amarin Corporation had annual revenue of $306.91M.
Revenue (ttm)
$277.46M
Revenue Growth
-23.04%
P/S Ratio
1.16
Revenue / Employee
$1,008,927
Employees
275
Market Cap
322.35M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
Dec 31, 2019 | 429.76M | 200.54M | 87.49% |
Dec 31, 2018 | 229.21M | 48.11M | 26.56% |
Dec 31, 2017 | 181.10M | 51.02M | 39.22% |
Dec 31, 2016 | 130.08M | 48.33M | 59.11% |
Dec 31, 2015 | 81.76M | 27.55M | 50.84% |
Dec 31, 2014 | 54.20M | 27.85M | 105.69% |
Dec 31, 2013 | 26.35M | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 703.37M |
Zynex | 188.68M |
Spok Holdings | 140.75M |
Scilex Holding Company | 47.05M |
Foghorn Therapeutics | 33.90M |
XOMA Corporation | 5.81M |
AMRN News
- 4 days ago - Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal - GlobeNewsWire
- 5 days ago - Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 - GlobeNewsWire
- 14 days ago - Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) - GlobeNewsWire
- 6 weeks ago - LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok - GlobeNewsWire
- 6 weeks ago - Amarin Board of Directors Announces CEO Transition - GlobeNewsWire
- 7 weeks ago - Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. - GlobeNewsWire
- 2 months ago - Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference - GlobeNewsWire
- 2 months ago - Amarin Reports First Quarter 2024 Business Update and Financial Results - GlobeNewsWire